These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22595153)

  • 21. Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model.
    Thomsen K; Christophersen L; Lerche CJ; Holmgaard DB; Calum H; Høiby N; Moser C
    Int J Antimicrob Agents; 2021 Jan; 57(1):106213. PubMed ID: 33256950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steady-State Therapy with Azithromycin or Low-Dose Prednisolone in Paediatric Cystic Fibrosis Patients: Inflammatory Markers and Disease Progression.
    Shmarina G; Pukhalsky A; Avakian L; Semykin S; Pukhalskaya D; Alioshkin V
    Int Arch Allergy Immunol; 2017; 172(1):45-54. PubMed ID: 28219060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4.
    Lawrence R; Sorrell T
    Lancet; 1993 Aug; 342(8869):465-9. PubMed ID: 8102430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study.
    Hillis GS; Pearson CV; Harding SA; Sutherland S; Ludlam CA; Marioni JC; Prescott RJ; Fox KA; Flapan AD
    Am Heart J; 2004 Jul; 148(1):72-9. PubMed ID: 15215794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis.
    Florescu DF; Murphy PJ; Kalil AC
    Pulm Pharmacol Ther; 2009 Dec; 22(6):467-72. PubMed ID: 19328860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Nguyen D; Emond MJ; Mayer-Hamblett N; Saiman L; Marshall BC; Burns JL
    Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients.
    Smith JW; Colombo JL; McDonald TL
    J Clin Lab Anal; 1992; 6(4):219-24. PubMed ID: 1403341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of ınflammation and fibrosis in non-alcoholic steatohepatitis?
    Bıçakçı E; Demirtaş CÖ; Çelikel Ç; Haklar G; Duman DG
    Turk J Gastroenterol; 2020 Oct; 31(10):681-687. PubMed ID: 33169705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
    Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
    Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients.
    Visca A; Bishop CT; Hilton S; Hudson VM
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):802-10. PubMed ID: 25633497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of azithromycin in patients with cystic fibrosis.
    Samson C; Tamalet A; Thien HV; Taytard J; Perisson C; Nathan N; Clement A; Boelle PY; Corvol H
    Respir Med; 2016 Aug; 117():1-6. PubMed ID: 27492507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
    Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
    JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
    Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW;
    Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azithromycin for improving pulmonary function in cystic fibrosis.
    Carr RR; Nahata MC
    Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
    Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
    Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.
    Cogen JD; Onchiri F; Emerson J; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M
    Ann Am Thorac Soc; 2018 Jun; 15(6):702-709. PubMed ID: 29474110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-reactive protein/albumin ratio is associated with lung function among children/adolescents with cystic fibrosis: a three-year longitudinal study.
    Ventura JC; Hauschild DB; Moreira EAM; Pereira LCR; Rosa AF; Barbosa E; Ludwig-Neto N; Rosa JSD; Fröde TS; Moreno YMF
    Sao Paulo Med J; 2018; 136(1):29-36. PubMed ID: 29267535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.
    Goyal V; Grimwood K; Ware RS; Byrnes CA; Morris PS; Masters IB; McCallum GB; Binks MJ; Smith-Vaughan H; O'Grady KF; Champion A; Buntain HM; Schultz A; Chatfield M; Torzillo PJ; Chang AB
    Lancet Respir Med; 2019 Sep; 7(9):791-801. PubMed ID: 31427252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
    Jain R; Beckett VV; Konstan MW; Accurso FJ; Burns JL; Mayer-Hamblett N; Milla C; VanDevanter DR; Chmiel JF;
    J Cyst Fibros; 2018 Jul; 17(4):484-491. PubMed ID: 29292092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.